Abstract:Bioactive peptides derived from food are promising health-promoting ingredients that can be used in functional foods and nutraceutical formulations. In addition to potency towards the selected therapeutic target, the bioavailability of bioactive peptides is a major factor regarding clinical efficacy. We have previously shown that a low molecular weight peptide fraction (LMWPF) from poultry by-product hydrolysate possesses angiotensin-1-converting enzyme (ACE-1) and dipeptidyl-peptidase 4 (DPP4) inhibitory activity. The present study aimed to investigate the bioavailability of the bioactive peptides in the LMWPF. Prior to investigation of bioavailability, a dipeptide YA was identified from this fraction as a dual inhibitor of ACE-1 and DPP4. Gastrointestinal (GI) stability and intestinal absorption of the bioactive peptides (i.e., YA as well as two previously reported bioactive dipeptides (VL and IY)) in LMWPF were evaluated using INFOGEST static in vitro digestion model and an intestinal Caco-2 cell monolayer, respectively. Analysis of peptides after in vitro digestion confirmed that the dipeptides were resistant to the simulated GI conditions. After 4 hours of incubation, the concentration of peptide from the apical side of the Caco-2 cell monolayer showed a significant decrease. However, the corresponding absorbed peptides were not detected on the basolateral side, suggesting that the peptides were not transported across the intestinal monolayer but rather taken up or metabolized by the Caco2 cells.Furthermore, when analyzing the gene expression of the Caco-2 cells upon peptide stimulation, a down-regulation of peptide transporters, the transcription factor CDX2, and the tight junction protein-1 (TJP1) were observed, suggesting specific effects of the peptides on the Caco-2 cells. The study demonstrated that bioactive dipeptides found in LMWPF were stable through in vitro GI digestion, however, the overall bioavailability may be hindered by inadequate uptake across the intestinal barrier.

Transport, Stability, and in Vivo Hypoglycemic Effect of a Broccoli-Derived DPP-IV Inhibitory Peptide VPLVM.

Dipeptidyl Peptidase IV(DPP IV): a Novel Emerging Target for the Treatment of Type 2 Diabetes

Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.

Food-derived dipeptidyl peptidase IV inhibitory peptides: Production, identification, structure-activity relationship, and their potential role in glycemic regulation

Effect of glucagon-like peptide-1 for the treatment of diabetes mellitus

Synthesis and bioactivity evaluation of dipeptidyl peptidase IV resistant glucagon-like peptide-1 analogues.

Peptide Analogues of VPP and IPP with Improved Glucose Uptake Activity in L6 Myotubes can be Released from Cereal Proteins

Discovery of Novel Dipeptidyl Peptidase-Iv Inhibitory Peptides Derived from Walnut Protein and Their Bioactivities in Vivo and in Vitro

A novel bifunctional peptide VAMP mined from hemp seed protein hydrolysates improves glucose homeostasis by inhibiting intestinal DPP-IV and increasing the abundance of

Identification, Screening, and Comprehensive Evaluation of Novel DPP-IV Inhibitory Peptides from the Tilapia Skin Gelatin Hydrolysate Produced Using Ginger Protease

Preparation, structural properties, and in vitro and in vivo activities of peptides against dipeptidyl peptidase IV (DPP-IV) and α-glucosidase: a general review

Hypoglycemic peptide preparation from Bacillus subtilis fermented with Pyropia: Identification, molecular docking, and in vivo confirmation

Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review

Novel Broccoli-Derived Peptides Hydrolyzed by Trypsin with Dual-Angiotensin I-Converting Enzymes and Dipeptidyl Peptidase-IV-Inhibitory Activities

An Orally Available Hypoglycaemic Peptide Taken Up by Caveolae Transcytosis Displays Improved Hypoglycaemic Effects and Body Weight Control in Db/db Mice

In vitro gastrointestinal stability and intestinal absorption of ACE-1 and DPP4 inhibitory peptides from poultry by-product hydrolysate

Novel Pentapeptide GLP‐1 (32–36) Amide Inhibits Β‐cell Apoptosis in Vitro and Improves Glucose Disposal in Streptozotocin‐Induced Diabetic Mice

Characterization of DPP-IV Inhibitory Peptides Using an in Vitro Cell Culture Model of the Intestine

Identification, rapid screening, docking mechanism and in vitro digestive stability of novel DPP-4 inhibitory peptides from wheat gluten with ginger protease

A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.

Study on the Mechanism of Interaction between Dipeptidyl Peptidase 4 and Inhibitory Peptides Based on Gaussian Accelerated Molecular Dynamic Simulation